Equities Analysts Offer Predictions for FOLD Q4 Earnings

Key Points

• Zacks Research has upgraded its Q4 2025 earnings estimate for Amicus Therapeutics from $0.07 to $0.08 per share, maintaining a "Strong-Buy" rating on the stock.
• Amicus Therapeutics has received mixed ratings from analysts, with one holding a Strong Buy rating, eight as Buy, and one as Sell.
• The stock currently has an average price target of $15.78, with a significant market cap of $2.55 billion and a recent trading price around $8.26.

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research increased their Q4 2025 earnings estimates for shares of Amicus Therapeutics in a note issued to investors on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.08 per share for the quarter, up from their prior forecast of $0.07. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' Q4 2026 earnings at $0.14 EPS and FY2026 earnings at $0.37 EPS.

FOLD has been the subject of a number of other reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of Amicus Therapeutics in a research note on Wednesday. Wall Street Zen upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, September 20th. Needham & Company LLC upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 price target for the company in a research report on Thursday, September 18th. Finally, Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $15.78.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $8.26 on Thursday. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $12.65. The company's 50 day moving average price is $7.66 and its two-hundred day moving average price is $6.91. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The stock has a market cap of $2.55 billion, a P/E ratio of -68.83 and a beta of 0.56.

Institutional Trading of Amicus Therapeutics

Several hedge funds have recently added to or reduced their stakes in FOLD. Wellington Management Group LLP boosted its holdings in shares of Amicus Therapeutics by 2.6% during the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company's stock worth $238,277,000 after purchasing an additional 738,623 shares during the period. Vestal Point Capital LP increased its stake in shares of Amicus Therapeutics by 178.4% during the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company's stock valued at $68,187,000 after purchasing an additional 7,625,000 shares in the last quarter. State Street Corp grew its holdings in shares of Amicus Therapeutics by 21.5% during the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company's stock valued at $66,285,000 after buying an additional 2,049,078 shares during the last quarter. Redmile Group LLC grew its holdings in shares of Amicus Therapeutics by 35.1% during the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company's stock valued at $77,795,000 after buying an additional 2,478,779 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Amicus Therapeutics by 20.7% during the second quarter. Bank of America Corp DE now owns 6,847,275 shares of the biopharmaceutical company's stock valued at $39,235,000 after buying an additional 1,172,596 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.